COMPUGEN LTD

Compugen Ltd. is a clinical-stage company focused on discovering and developing new therapies. The company uses its AI/ML-powered computational discovery platform, Unigen, to find new drug targets and create treatments for cancer immunotherapy. Compugen's immuno-oncology pipeline includes four programs currently in clinical trials: COM701, COM902, rilvegostomig, and GS-0321 (formerly COM503). COM701 is an anti-PVRIG antibody, and COM902 is a therapeutic anti-TIGIT antibody. Both have been tested for treating solid tumors as a single treatment and in combinations, including dual blockades (PVRIG/PD-1, PVRIG/TIGIT) and triple blockades (PVRIG/PD-1/TIGIT). The final patient in a clinical trial evaluating the triple combination of COM701, COM902, and pembrolizumab, which started in 2023, received their last dose in January 2026. Compugen was incorporated in Israel on February 10, 1993, and its main offices are in Holon, Israel. Its U.S. subsidiary, Compugen USA, Inc., is located in San Francisco, CA. Capital expenditures for the years ended December 31, 2025, 2024, and 2023 were $0.3 million, $0.1 million, and $0.2 million, respectively. As of December 31, 2025, the company had no significant commitments for future capital expenditures.